SARAH LENHART-WEBSTER: Open Payments
NPI 1558012831 · AUBURN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$303 in 15 payments from 8 companies in 2025. Trend: 2023 $903 · 2024 $206 · 2025 $303
Food & beverage: $303
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $57 |
| ABBVIE INC. | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: ARISTADA, CAPLYTA, Jornay PM, Auvelity, QULIPTA, UZEDY, TRINTELLIX, VRAYLAR.
Industry payments across IN — which companies pay providers there.
